Workflow
内镜微创诊疗
icon
Search documents
安杰思收盘上涨1.31%,滚动市盈率17.23倍,总市值51.16亿元
Sou Hu Cai Jing· 2025-06-24 14:03
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjiasi Medical Technology Co., Ltd., which operates in the medical device industry, specifically focusing on minimally invasive endoscopic diagnostic and therapeutic instruments [1][2] - As of June 24, Anjiasi's closing price was 63.18 yuan, reflecting a 1.31% increase, with a rolling price-to-earnings (PE) ratio of 17.23 times and a total market capitalization of 5.116 billion yuan [1] - The average PE ratio for the medical device industry is 49.12 times, with a median of 36.07 times, positioning Anjiasi at the 41st rank within the industry [1][2] Group 2 - As of the first quarter of 2025, 11 institutions held shares in Anjiasi, including 6 funds and 5 other entities, with a total holding of 17.7325 million shares valued at 1.26 billion yuan [1] - Anjiasi's main products include GI series, EMR/ESD series, ERCP diagnostic series, and therapeutic instruments, contributing to its revenue growth [1] - The latest financial report for the first quarter of 2025 shows Anjiasi achieved an operating income of 129 million yuan, a year-on-year increase of 15.27%, and a net profit of 56.2483 million yuan, reflecting a year-on-year growth of 6.57%, with a gross profit margin of 70.68% [1]
6.37亿!增长25.14%!安杰思最新年报
思宇MedTech· 2025-04-23 07:04
报名:首届全球骨科大会 | 参会须知 报名:首届全球心血管大会 | 重磅亮点 合作伙伴征集:2025全球手术机器人大会 2025年4月23日, 安杰思 发布了2024年年报。 # 公司业务核心驱动力 # 关于安杰思 杭州安杰思医学科技股份有限公司是一家专注于内镜微创诊疗器械研发、生产和销售的高新技术企业,成立于 2010年12月,2023年5月成功上市。公司位于浙江省杭州市余杭区,其产品涵盖止血闭合类、EMR/ESD 类、活检类、ERCP类及仪器类等多个品类,广泛应用于 消化内镜、呼吸内镜、耳鼻喉内镜、泌尿内镜和妇 科内镜 等五大领域。安杰思高度重视技术创新,截至2024年末,累计申请专利367项,其中发明专利239 项,有效授权专利100项,48%以上专利已应用于产品,为公司带来了显著的市场竞争力。 # 财务与市场表现 主要财务数据 : 2024年公司营业收入为 6.37亿 元,同比 增长25.14% ; 归属于上市公司股东的净利 润为2.93亿元,同比增长35.06%;归属于上市公司股东的扣除非经常性损益的净利润为2.73亿元,同比 增长28.62%;经营活动产生的现金流量净额为3.16亿元,同比增长42 ...
6.37亿!增长25.14%!安杰思最新年报
思宇MedTech· 2025-04-23 07:04
Financial and Market Performance - In 2024, the company's operating revenue reached 637 million yuan, representing a year-on-year growth of 25.14% [2] - The net profit attributable to shareholders was 293 million yuan, an increase of 35.06% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 273 million yuan, up 28.62% year-on-year [2] - The net cash flow from operating activities was 316 million yuan, reflecting a growth of 42.61% [2] Core Business Drivers - The company focuses on the research, development, production, and sales of minimally invasive diagnostic and therapeutic instruments, with a wide range of products used in various endoscopic fields [1] - The aging population, increased health awareness, and improved medical insurance levels are driving demand for endoscopic minimally invasive diagnostic and therapeutic instruments, providing significant market opportunities for the company [2] Company Overview - Hangzhou Anjiasi Medical Technology Co., Ltd. was established in December 2010 and successfully went public in May 2023 [1] - The company has applied for a total of 367 patents, with 239 being invention patents, and over 48% of these patents have been applied to products, enhancing its market competitiveness [1][2] Profitability - The gross profit margin for 2024 was 72.11%, an increase of 1.24 percentage points year-on-year [2] - The net profit margin was 46.09%, up 3.38 percentage points compared to the previous year [2] Expense Situation - The company's period expenses for 2024 amounted to 132 million yuan, an increase of 23.48 million yuan year-on-year [2] - The period expense ratio was 20.81%, a decrease of 0.61 percentage points year-on-year [2] - Research and development expenses increased by 43.53% year-on-year, indicating a strong focus on innovation [2] Brand and Customer Resources - The company has established a strong brand image and customer resources through years of market accumulation, forming long-term stable partnerships with numerous medical institutions [2]
安杰思:安杰思首次公开发行股票并在科创板上市招股说明书
2023-05-15 11:34
本次发行股票拟在科创板上市,科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点,投资者面临较大的市场风险。投资者应 充分了解科创板的投资风险及本公司所披露的风险因素,审慎作出投资决定。 杭州安杰思医学科技股份有限公司 (浙江省杭州市余杭区康信路 597 号 5 幢、6 幢(除 103 室、202 室)) 首次公开发行股票并在科创板上市 招股说明书 保荐人(主承销商) 广东省深圳市福田区中心三路 8 号卓越时代广场(二期)北座 杭州安杰思医学科技股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见,均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证,也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定,股票依法发行后,发行人经营与收益的变化,由发行 人自行负责;投资者自主判断发行人的投资价值,自主作出投资决策,自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 杭州安杰思医学科技股份有限公司 招股说明书 本次发 ...
安杰思:安杰思首次公开发行股票并在科创板上市招股意向书
2023-04-26 11:34
本次发行股票拟在科创板上市,科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点,投资者面临较大的市场风险。投资者应 充分了解科创板的投资风险及本公司所披露的风险因素,审慎作出投资决定。 杭州安杰思医学科技股份有限公司 (浙江省杭州市余杭区康信路 597 号 5 幢、6 幢(除 103 室、202 室)) 首次公开发行股票并在科创板上市 招股意向书 广东省深圳市福田区中心三路 8 号卓越时代广场(二期)北座 保荐人(主承销商) 杭州安杰思医学科技股份有限公司 招股意向书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见,均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证,也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定,股票依法发行后,发行人经营与收益的变化,由发行 人自行负责;投资者自主判断发行人的投资价值,自主作出投资决策,自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 杭州安杰思医学科技股份有限公司 招股意向书 本次发 ...
杭州安杰思医学科技股份有限公司_科创板首次公开发行股票招股说明书(注册稿)
2023-03-28 11:47
本次发行股票拟在科创板上市,科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点,投资者面临较大的市场风险。投资者 应充分了解科创板的投资风险及本公司所披露的风险因素,审慎作出投资决 定。 杭州安杰思医学科技股份有限公司 (浙江省杭州市余杭区康信路 597 号 5 幢、6 幢(除 103 室、202 室)) 首次公开发行股票并在科创板上市 招股说明书 (注册稿) 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。 本招股说明书(注册稿)不具有据以发行股票的法律效力,仅供预先披露之 用。投资者应当以正式公告的招股说明书全文作为作出投资决定的依据。 保荐人(主承销商) 广东省深圳市福田区中心三路 8 号卓越时代广场(二期)北座 杭州安杰思医学科技股份有限公司 招股说明书(注册稿) 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见,均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证,也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定,股票依法发行后,发行人经营与收 ...